FDA accepts BLA for BMS’ subcutaneous nivolumab to treat solid tumours

A regulatory decision on the approval for BMS’ subcutaneous nivolumab under the Prescription Drug User Fee Act (PDUFA) is expected on 28 February next year. Credit: Bristol-Myers Squibb Company.